Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in COVID-19 Patients with and without Bacterial Sepsis

Basit Öğe Kaydı
dc.authorid0000-0003-2119-3801
dc.authorid0000-0001-9750-1028
dc.contributor.authorKoc, Suna
dc.contributor.authorHanikoglu, Ferhat
dc.contributor.authorDokur, Mehmet
dc.contributor.authorPolat, Yalcin
dc.contributor.authorCelebi, Serdar
dc.contributor.authorKoc, Sena G.
dc.contributor.authorKupeli, Ilke
dc.date.accessioned2026-01-24T12:26:52Z
dc.date.available2026-01-24T12:26:52Z
dc.date.issued2022
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: In this retrospective study, we aimed to compare the laboratory and clinical results of cytokine hem-adsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis. Methods: The levels of PCT, CRP, and ferritin were determined as indicators of infection/sepsis; the levels of in-terleukins (IL-6, IL-8 and IL-10, and TNF-??) were determined as indicators of cytokine storm were compared. APACHE score, SOFA score, and mortality rates were compared for the progression of the disease in 23 COVID-19 patients. Results: The therapy was generally successful in reducing the levels of IL-6, IL-8, IL-10, and TNF-?? but the levels measured after the procedure did not differ among the patients with or without sepsis, suggesting that the pres-ence of sepsis did not affect the efficacy and function of the cytokine hemadsorption procedure in COVID-19 pa-tients. All parameters were reduced after the procedure except the levels of PCT and ferritin and mortality rates of patients diagnosed with sepsis. The level of PCT was significantly higher in these patients compared with the patients without sepsis while the ferritin and mortality did not show any significant difference between the two groups, suggesting that the cytokine hemadsorption may be safe in the treatment of critical COVID-19 patients. Conclusions: As a result, the progression of sepsis in COVID-19 may be avoided with cytokine hemadsorption ap-plied as an immunomodulator therapy. However, this therapy should be further explored and validated prior to its introduction to everyday clinical practice when the epidemic conditions end.
dc.identifier.doi10.7754/Clin.Lab.2022.211249
dc.identifier.issn1433-6510
dc.identifier.pmid36250840
dc.identifier.scopus2-s2.0-85140271212
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2022.211249
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4959
dc.identifier.wosWOS:000920433700001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherClin Lab Publ
dc.relation.ispartofClinical Laboratory
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectClinical Characteristics
dc.subjectSeptic Shock
dc.subjectHemoadsorption
dc.subjectStorm
dc.subjectImprovement
dc.subjectRescue
dc.titleComparison of Cytokine Hemadsorption as an Immunomodulator Therapy in COVID-19 Patients with and without Bacterial Sepsis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu